The Xyrem® (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017

Background Sodium oxybate, which is approved for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy, is available in the USA only through the restricted-distribution Xyrem ® Risk Evaluation and Mitigation Strategy Program (Xyrem REMS Program, XRP). The XRP require...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs - real world outcomes 2021-03, Vol.8 (1), p.15-28
Hauptverfasser:	Strunc, Michael J., Black, Jed, Lillaney, Prasheel, Profant, Judi, Mills, Sherice, Bujanover, Shay, Thorpy, Michael J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidepressants Certification Controlled substances Counseling Drug stores Education Enrollments FDA approval Hallucinations Internal Medicine Medicine Medicine & Public Health Original Original Research Article Patients Pharmacists Pharmacology/Toxicology Pharmacotherapy Prescription drugs Shipments Sleep disorders Sodium
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!